Cargando…

Synthesis, Physicochemical and Biological Study of Gallium-68- and Lutetium-177-Labeled VEGF-A(165)/NRP-1 Complex Inhibitors Based on Peptide A7R and Branched Peptidomimetic

Neuropilin-1 (NRP-1) is a surface receptor found on many types of cancer cells. The overexpression of NRP-1 and its interaction with vascular endothelial growth factor-165 (VEGF(165)) are associated with tumor growth and metastasis. Therefore, compounds that block the VEGF(165)/NRP-1 interaction rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masłowska, Katarzyna, Witkowska, Ewa, Tymecka, Dagmara, Halik, Paweł Krzysztof, Misicka, Aleksandra, Gniazdowska, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779334/ https://www.ncbi.nlm.nih.gov/pubmed/35056995 http://dx.doi.org/10.3390/pharmaceutics14010100

Ejemplares similares

The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy
por: Masłowska, Katarzyna, et al.
Publicado: (2021)

Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy
por: Masłowska, Katarzyna, et al.
Publicado: (2023)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Novel NK1R-Targeted (68)Ga-/(177)Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships
por: Matalińska, Joanna, et al.
Publicado: (2022)

In Vitro Biological Evaluation of Aprepitant Based (177)Lu-Radioconjugates
por: Halik, Paweł K., et al.
Publicado: (2022)

Bifunctional Opioid/Melanocortin Peptidomimetics for Use in Neuropathic Pain: Variation in the Type and Length of the Linker Connecting the Two Pharmacophores
por: Witkowska, Ewa, et al.
Publicado: (2022)

Urea-Peptide Hybrids as VEGF-A(165)/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties
por: Puszko, Anna K., et al.
Publicado: (2020)

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
por: Baur, Benjamin, et al.
Publicado: (2014)

Imaging and treatment with (68)Gallium and (177)Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung
por: Kumaran, Arjunan, et al.
Publicado: (2022)

Triazolopeptides Inhibiting the Interaction between Neuropilin-1 and Vascular Endothelial Growth Factor-165
por: Fedorczyk, Bartlomiej, et al.
Publicado: (2019)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Image Findings of a Rare Case of Neuroendocrine Tumor Metastatic to Orbital Extraocular Muscle in Gallium-68 DOTANOC Positron Emission Tomography/Computed Tomography and Therapy with Lutetium-177 DOTATATE
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2017)

VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation
por: Fantin, Alessandro, et al.
Publicado: (2017)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
por: Halik, Paweł K., et al.
Publicado: (2020)

Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain
por: Piotrowska, Anna, et al.
Publicado: (2021)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
por: Moussaron, Albert, et al.
Publicado: (2021)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy
por: Cappon, Derek John, et al.
Publicado: (2023)

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023)

Physicochemical and Biological Study of (99m)Tc and (68)Ga Radiolabelled Ciprofloxacin and Evaluation of [(99m)Tc]Tc-CIP as Potential Diagnostic Radiopharmaceutical for Diabetic Foot Syndrome Imaging
por: Koźmiński, Przemysław, et al.
Publicado: (2021)

VEGF(189) binds NRP1 and is sufficient for VEGF/NRP1-dependent neuronal patterning in the developing brain
por: Tillo, Miguel, et al.
Publicado: (2015)

Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine
por: Halik, Paweł Krzysztof, et al.
Publicado: (2020)

Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report
por: Gezer, Emre, et al.
Publicado: (2019)

β(2)-Homo-Amino Acid Scan of µ-Selective Opioid Tetrapeptide TAPP
por: Tymecka, Dagmara, et al.
Publicado: (2020)

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy
por: Majkowska-Pilip, Agnieszka, et al.
Publicado: (2019)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF(165) and downregulating VEGF(165b)
por: Quan, Bingxuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v52htqa99ij3vaapnp6ek347jh